Search Results

You are looking at 121 - 130 of 2,623 items for :

  • Refine by Access: All x
Clear All
Full access

David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman

associated with poor outcome among patients with glioblastoma. 30 , 31 VEGF-A isoforms generated by alternative splicing can also originate from host sources, such as invading macrophages and platelets, whereas tumor stroma can sequester larger isoforms that

Full access

Ajeet Gajra, Alissa S. Marr, and Apar Kishor Ganti

patient populations that respond differently to treatment and have different outcomes. 7 Another challenge in interpreting the trial evidence for this group of patients is the subjectivity associated with assigning a PS to any given patient. A recent

Full access

Aruni Ghose, John Hayes, Nicolas Omorphos, Nikhil Vasdev, and Sharma Anand

revolutionised the treatment landscape. There exists a dearth of literature of real-world data on clinical trials focussing on immunotherapy treatment outcomes. Methods : Our study population included mUC patients treated at two large North West London Cancer

Full access

Philippe E. Spiess

NCCN Panel on bladder and penile cancers. With the use of non–evidence-based treatment approaches, outcomes can widely vary. To clarify some of the controversies associated with the treatment of penile cancer, NCCN has created inaugural NCCN Clinical

Full access

Michael Grimm, Kai Johnson, Patrick Schnell, Ashley Pariser, Margaret Gatti-Mays, Jeffrey VanDeusen, Nicole Williams, Daniel Stover, Sagar Sardesai, Robert Wesolowski, Preeti Sudheendra, Bhuvaneswari Ramaswamy, Ko Un Park, Sachin R Jhawar, Amy Kerger, and Mathew A Cherian

characteristics, treatment regimens, and survival outcomes between non-metastatic IBC patients and comprehensively matched patients with stage III invasive non-IBC based on age, stage, and biomarker status. Results : A total of 165 patients (84 IBC, 81 non

Full access

Zhihui Gao, Shen Sheng, Liu Han, Ni Xiaoling, Suo Tao, Wang Yueqi, and Houbao Liu

Background and aim: Indications of preoperative biliary drainage (PBD) for malignant obstructive jaundice are still controversial. The present study aims to assess the impact of preoperative biliary drainage on postoperative outcome, to define the

Full access

Henry Soo-Min Park

Over the course of the past quarter century, an increasing number of observational studies have been published investigating how surgeon and hospital experience can influence the outcomes of patients undergoing complex surgeries. Early studies

Full access

Mackenzie Taychert, Ankita Aggarwal, David Tabagari, Urja Nagadia, Sai Gajagowni, Venkata Vosuri, and Kushal Naha

Introduction: BRAF mutations in advanced stage colorectal cancers are observed in 8-12% of patients and BRAF V600E is the most frequent alteration. This mutation confers poor prognosis and treatment outcomes with routine systemic chemotherapy

Full access

Justine M. Kahn and Melissa Beauchemin

, adolescents, and young adults (AYA; aged 15–39 years) with HL exceed 95%, with event-free survival (EFS) rates >85%. 4 The treatment successes in HL are attributed, in part, to 4 key factors: (1) research to identify disease-related predictors of poor outcome

Full access

Joseph C. Alvarnas and Patrick A. Brown

Outcomes for patients with acute lymphoblastic leukemia (ALL) have improved dramatically over the past 4 decades. Overall 5-year relative survival rates for patients with ALL have increased from 40.6% during the period between 1975 and 1977 to 70